Julia S, James U. Direct oral anticoagulants: a quick guide. Eur Cardiol. 2017;12(1):40–5.

Article  PubMed  PubMed Central  Google Scholar 

Aronis KN, Hylek EM. Evidence gaps in the era of non-vitamin K oral anticoagulants. J Am Heart Assoc. 2018;7(3):e007338.

Article  PubMed  PubMed Central  Google Scholar 

Ma T, Liu C, Jiang T, Qin H, Wu R, Zhou P. Comparative risk for intracranial hemorrhage related to new oral anticoagulants: a network meta-analysis. Medicine (Baltimore). 2021;100(12):e24522.

Article  CAS  PubMed  Google Scholar 

Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8.

Article  CAS  PubMed  Google Scholar 

Wilson D, Charidimou A, Shakeshaft C, Ambler G, White M, Cohen H, et al. CROMIS-2 collaborators. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology. 2016;86(4):360–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milling TJ Jr, Spyropoulos AC. Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. Am J Emerg Med. 2016;34(11):19–25.

Article  PubMed  PubMed Central  Google Scholar 

Heo YA. Andexanet alfa: first global approval. Drugs. 2018;78(10):1049–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tao J, Bukanova EN, Akhtar S. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors. J Intensive Care. 2018;6(1):34.

Article  PubMed  PubMed Central  Google Scholar 

Rauh JL, Torosian T, Thompson A, Evangelista M, Hoth J. The effect of 4-factor prothrombin complex concentrate to reverse factor Xa inhibitors in patients with traumatic intracranial hemorrhage. Am Surg. 2024;90(7):1904–6.

Article  PubMed  Google Scholar 

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor xa inhibitor activity. N Engl J Med. 2015;373(25):2413–24.

Article  CAS  PubMed  Google Scholar 

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frontera JA, Bhatt P, Lalchan R, Yaghi S, Ahuja T, Papadopoulos J, et al. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis. 2020;49(1):121–31.

Article  CAS  PubMed  Google Scholar 

Milling TJ Jr, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, et al. ANNEXA-4 Investigators. Final study report of andexanet alfa for major bleeding with factor xa inhibitors. Circulation. 2023;147(13):1026–38.

Article  CAS  PubMed  Google Scholar 

Ammar AA, Ammar MA, Owusu KA, Brown SC, Kaddouh F, Elsamadicy AA, et al. andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage. Neurocrit Care. 2021;35(1):255–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pham H, Medford WG, Horst S, Levesque M, Ragoonanan D, Price C, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. Am J Emerg Med. 2022;55:38–44.

Article  PubMed  Google Scholar 

Parsels KA, Seabury RW, Zyck S, Miller CD, Krishnamurthy S, Darko W, et al. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: a single-center, retrospective, matched cohort analysis. Am J Emerg Med. 2022;55:16–9.

Article  PubMed  Google Scholar 

Vestal ML, Hodulik K, Mando-Vandrick J, James ML, Ortel TL, Fuller M, et al. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis. 2022;53(1):167–75.

Article  CAS  PubMed  Google Scholar 

Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, et al. ANNEXA-I Investigators. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. 2024;390(19):1745–55.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71): n71.

Article  PubMed  PubMed Central  Google Scholar 

Ottawa Hospital Research Institute [Internet]. [cited 2024 Jun 23]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

Article  CAS  PubMed  Google Scholar 

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

Article  PubMed  PubMed Central  Google Scholar 

revman.cochrane.org/ [Internet]. [cited 2024 Apr 4]. Available from: https://revman.cochrane.org/

OpenMeta[Analyst]-CEBM @ Brown [Internet]. [cited 2024 Apr 4]. Available from: http://www.cebm.brown.edu/openmeta/

Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 2022;26(1):180.

Article  PubMed  PubMed Central  Google Scholar 

Dobesh PP, Fermann GJ, Christoph MJ, Koch B, Lesén E, Chen H, et al. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. Res Pract Thromb Haemost. 2023;7(6):102192.

Article  PubMed  PubMed Central  Google Scholar 

Barra ME, Das AS, Hayes BD, Rosenthal ES, Rosovsky RP, Fuh L, et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost. 2020;18(7):1637–47.

Article  CAS  PubMed  Google Scholar 

Coleman CI, Dobesh PP, Danese S, Ulloa J, Lovelace B. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. Fut Cardiol. 2021;17(1):127–35.

Article  CAS  Google Scholar 

Irizarry-Gatell VM, Bacchus MW, De Leo EK, Zhang Y, Lagasse CA, Khanna AY, et al. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage. Blood Coagul Fibrinolysis. 2024;35(3):94–100.

Article  CAS  PubMed  Google Scholar 

Koo SJ, Hussain Y, Booth DY, Desai P, Oh ES, Rios J, et al. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal. J Am Pharm Assoc. 2024;64(2):395–401.

Article  CAS